Navigation Links
Soligenix Announces Issuance of US Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders

PRINCETON, N.J., Sept. 13, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the company), a development stage biopharmaceutical company announced today that the US Patent Office granted patent 8,263,582 entitled "Method of Treating Inflammatory Disorders of the Gastrointestinal Tract using Topically Active Corticosteroids." The new patent's main claims cover the use of beclomethasone dipropionate (BDP) in orally administered dosage forms that act concurrently in both the upper and lower gastrointestinal tract. These dosage forms include the Company's oral formulation of BDP, a topically active corticosteroid, currently in development for pediatric Crohn's disease, acute radiation enteritis, and gastrointestinal Graft-versus-Host disease (GVHD).

"The granting of this patent marks a key addition to our intellectual property portfolio in the field of topically active steroids," stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. "It demonstrates the novelty and utility of our two-tablet system comprising an immediate release and a delayed release combination of oral BDP and underpins our approach to treating multiple inflammatory gastrointestinal disorders such as pediatric Crohn's disease."

In addition to issued patents and pending worldwide patent applications held by or exclusively licensed to Soligenix, BDP also benefits from several orphan drug designations in the US and abroad, including SGX203 for the treatment of pediatric Crohn's disease, which provides for seven years of post-approval market exclusivity in the US.

About Oral BDP
Beclomethasone dipropionate (BDP) is a highly potent, topically active corticosteroid that has a local effect on inflamed tissue. BDP has been marketed in the US and worldwide since the early 1970s as the active pharmaceutical ingredient in a nasal spray and in a metered-dose inhaler for the treatment of patients with allergic rhinitis and asthma.  Soligenix is currently developing oral formulations of BDP, including its proprietary two-tablet system specifically designed for delivery of BDP throughout the small bowel and the colon.   

About Soligenix, Inc.
Soligenix is a development stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix's lead product, orBec® (oral beclomethasone dipropionate), is a potent, locally acting corticosteroid that has been initially developed for the treatment of gastrointestinal Graft-versus-Host disease (GI GVHD), a common and potentially life-threatening complication of hematopoietic cell transplantation. Soligenix is also developing proprietary formulations of oral BDP for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including pediatric Crohn's disease (SGX203) and acute radiation enteritis (SGX201), which is the subject of a recently completed National Cancer Institute (NCI)-supported Phase 1/2 clinical trial.

Through its BioDefense Division, Soligenix is developing countermeasures pursuant to the Biomedical Advanced Research and Development Authority (BARDA) Strategic Plan of 2011-2016 for inclusion in the US government's Strategic National Stockpile. Soligenix's lead biodefense products in development are a recombinant subunit vaccine called RiVax™, which is designed to protect against the lethal effects of exposure to ricin toxin and VeloThrax™, a vaccine against anthrax exposure. RiVax™ has been shown to be well tolerated and immunogenic in two Phase 1 clinical trials in healthy volunteers. Both RiVax™ and VeloThrax™ are currently the subject of a $9.4 million National Institute of Allergy and Infectious Diseases (NIAID) grant supporting development of Soligenix's new vaccine heat stabilization technology known as ThermoVax™. Soligenix is also developing OrbeShield™ for the treatment of gastrointestinal acute radiation syndrome (GI ARS) under a $600,000 NIAID Small Business Innovation Research (SBIR) grant. OrbeShield™ has previously demonstrated statistically significant preclinical survival results in two separate canine GI ARS studies funded by the NIH.

For further information regarding Soligenix, Inc., please visit the Company's website at

This press release contains forward-looking statements that reflect Soligenix, Inc.'s current expectations about its future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes," "intends," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. Soligenix cannot assure you that it will be able to successfully develop or commercialize products based on its technology, particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, or that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program. These and other risk factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, Soligenix's reports on Forms 10-Q and 10-K. Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

SOURCE Soligenix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Soligenix Reports Second Quarter 2012 Financial Results and Highlights Recent Accomplishments
2. Soligenix Reports First Quarter 2012 Financial Results and Highlights Recent Accomplishments
3. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
4. Henry Schein Announces New $500 Million Credit Facility
5. BioDelivery Sciences Announces Positive Results of Pivotal Pharmacokinetic Study Comparing BEMA Buprenorphine/Naloxone (BNX) to Suboxone
6. Biodel Announces Phase 2 Clinical Trial Initiation Of Ultra-Rapid-Acting Insulin Candidate BIOD-123
7. Simcere Pharmaceutical Group Announces Appointment of New Chief Executive Officer
8. Edison Pharmaceuticals Announces Positive Results of EPI-743 Phase 2A Leigh Syndrome Clinical Trial
9. Elbit Imaging Ltd. Announces Standard & Poors Maalot Changes Rating of Companys Notes
10. 3SBio Inc. Announces Receipt of "Going Private" Proposal at $15 Per ADS
11. IncellDx, Inc. Announces an Agreement with BioReference Laboratories, Inc. to Conduct a 10,000 Sample Study Using a Slideless Pap Smear
Post Your Comments:
(Date:11/30/2015)... , 1 décembre 2015 ... exposition et conférence d,Asie portant sur ... sur l,industrie manufacturière, se tiendra à ... 20 au 22 avril 2016. ... Photo - ...
(Date:11/30/2015)... , December 1, 2015 ... adds "Endometriosis - Pipeline Review, H2 ... overview on therapeutic pipeline of Endometriosis and ... effective counter strategies to gain competitive advantage. ... targets and MOAs to produce first-in-class and ...
(Date:11/30/2015)... CUPERTINO, Calif. , Nov. 30, 2015 ... announced today that Matt Hogan , ... the Oppenheimer Healthcare Conference on Tuesday, December ... conference is being held at the Westin ... will also be available for one-on-one meetings ...
Breaking Medicine Technology:
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... RoamRight, a ... up with Public Television’s Travel With Kids to promote family vacations ... Simmons family as they explore international destinations and educate families about the people and ...
(Date:11/30/2015)... ... November 30, 2015 , ... A novel class of ... be effective in fighting methicillin-resistant Staphylococcus aureus (MRSA), one of the major drug-resistant ... that small molecule analogs that target the functions of SecA, a central part ...
(Date:11/30/2015)... Plains, NJ (PRWEB) , ... November 30, 2015 , ... ... in a comfortable and convenient setting. , When you have dental problems, you need ... the field and can effectively diagnose and treat your needs, a friendly dentist who ...
(Date:11/30/2015)... ... ... Using a combination of two blood sugar tests rather than a single test ... study by researchers at the School of Public Health at Georgia State University. , ... Glucose Tests ,” published in Frontiers in Public Health, the researchers noted that 24 ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... general dentistry out of Glen Ridge, NJ. He has both advanced training ... optimal mastication. He is also an expert in cosmetic dentistry. He is ...
Breaking Medicine News(10 mins):